Inspira Technologies has announced that the Japan Patent Office has granted Patent No. 7777598, covering the Company’s novel Convertible Dual Lumen Cannula device and method of use, securing exclusive rights in one of the world’s most advanced medical device markets.
The patent grants Inspira exclusive commercial rights in the patented Dual Lumen Cannula technology in Japan through 2041. This milestone complements the Company’s existing U.S. Patent (granted in 2023), further enhancing a unified protective barrier across two of the world’s largest healthcare economies.
Strategically, this IP supports the potential standalone commercialisation of the cannula as a high-value disposable product, in addition to its integration into the INSPIRA ART System.
Inspira’s patented technology features a unique mechanism that allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly, after insertion. This innovative design is engineered to allow physicians to switch modes without the need for additional incisions, potentially reducing infection risks, procedural complications, and hospital costs compared to traditional dual-lumen solutions.
“In today’s market, traditional dual lumen cannulas are extremely expensive to manufacture. Our patented convertible device offers the market more affordable solution that could enhance patient safety and procedural efficiency,” said Dagi Ben-Noon, CEO of Inspira Technologies. “With proprietary protection now locked in both the U.S. and Japan, markets with some of the most demanding regulatory standards, we have solidified the foundation for both our respiratory support platforms and future disposable revenue streams.”
